Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 1,461

Today, the conjunction of climate change, the advent of artificial intelligence and the capacity to import human purposiveness into evolution through the reading and rewriting of our own genome are, like the first leaps in technology and their consequences, stirring a search for the sacred that frames both the limits and potentialities of what it means to be human. As the Polish thinker Leszek Kołakowski sagely put it, without a sense of the sacred, culture loses all sense.

For this reason, he posited in a conversation some years ago at All Souls College in Oxford, that “mankind can never get rid of the need for religious self-identification. … Who am I, where did I come from, where do I fit in, why am I responsible, what does my life mean, how will I face death? Religion is a paramount aspect of human culture. Religious need cannot be excommunicated from culture by rationalist incantation.”

In this, Rees agrees. Far from consigning faith to the past, science fiction plumbs its future. Where technology and its consequences go, the religious imagination will follow.

Read more | >

When Dr. Robert Murphy first started researching biochemistry and drug development in the late 1970s, creating a pharmaceutical compound that was effective and safe to market followed a strict experimental pipeline that was beginning to be enhanced by large-scale data collection and analysis on a computer.

Now head of the Murphy Lab for computational biology at Carnegie Mellon University (CMU), Murphy has watched over the years as data collection and artificial intelligence have revolutionized this process, making the drug creation pipeline faster, more efficient, and more effective.

Recently, that’s been thanks to the application of machine learning—computer systems that learn and adapt by using algorithms and statistical models to analyze patterns in datasets—to the drug development process. This has been notably key to reducing the presence of side effects, Murphy says.

Read more | >

The timeframe for reinfection is fundamental to numerous aspects of public health decision making. As the COVID-19 pandemic continues, reinfection is likely to become increasingly common. Maintaining public health measures that curb transmission—including among individuals who were previously infected with SARS-CoV-2—coupled with persistent efforts to accelerate vaccination worldwide is critical to the prevention of COVID-19 morbidity and mortality.

US National Science Foundation.

Read more | >

And, depending on how further studies progress, it could be implemented via gene therapy.

Early-stage pancreatic cancer has a ‘reset button’

“These findings open up the possibility of designing a new gene therapy or drug because now we can convert cancerous cells back into their normal state,” said Professor Bumsoo Han of Purdue’s mechanical engineering, who is also the program leader for the university’s Center for Cancer Research, in a blog post shared on the university’s official website. Han has also received a courtesy appointment in biomedical engineering, according to the post. The new time machine (speaking figuratively) from Han’s lab is a lifelike reproduction of a specific structure of the pancreas, called the acinus, which secretes and produces digestive enzymes into the small intestine. When pancreatic cancer strikes, it typically comes from chronic inflammation, which is caused by a mutation that tricks the digestive enzymes to begin digesting the pancreas itself. This is bad.

Read more | >

Brains aren’t the easiest of organs to study, what with their delicate wiring and subtle whispering of neurotransmitter messages. Now, this research could be made a little easier, as we’ve learned we can swap some critical chemical systems with the host animal being none the wiser.

In a proof-of-concept study run by a team of US researchers, the microscopic worm Caenorhabditis elegans was genetically gifted pieces of a nervous system taken from a radically different creature – a curious freshwater organism known as Hydra.

The swap wasn’t unlike teaching a specific brain circuit a foreign language, and finding it performs its job just as well as before.

Read more | >

Genetic information can be messy. Mapping proteins could offer a clearer view of what’s driving cancer.

Scientists have unveiled new maps of the protein networks underlying different types of cancer, offering a potentially clearer way to see what’s driving the disease and to find therapeutic targets.

Sequencing the genetic information of tumors can provide a trove of data about the mutations contained in those cancer cells. Some of those mutations help doctors figure out the best way to treat a patient, but others remain more of a mystery than a clear instruction manual. Many are exceedingly rare, or there are so many mutations it’s not clear what’s fueling the cancer.

Read more | >

Developing drugs for a range of tauopathies — dr leticia toledo-sherman, senior director, drug discovery, tau consortium, rainwater charitable foundation.

Dr. Leticia Toledo-Sherman is Senior Director of Drug Discovery of the Tau Consortium (https://tauconsortium.org/) for The Rainwater Charitable Foundation (https://rainwatercharitablefoundation.org/medical-research) and also holds an appointment as Adjunct Assistant Professor of Neurology at UCLA.

Dr. Toledo-Sherman leads drug discovery activities for an international network of scientists working to develop therapies for Tauopathies, a group of neurodegenerative disorders characterized by the deposition of abnormal Tau protein in the brain.

Previously, Dr. Toledo-Sherman was Director of Medicinal Chemistry and Computer-Aided Drug Design at the CHDI Foundation, leading drug discovery programs for therapeutic development in Huntington’s Disease (HD). At CHDI, she also led a structural biology initiative critical to the understanding of the relationship between structure and biological function of huntingtin, the protein that when mutated causes HD.

Prior to joining CHDI, Dr. Toledo-Sherman was Executive Director of Chemistry at Lymphosign (now part of Pharmascience Inc), a privately held biotechnology company that applied rational design principles to the development of therapeutics for blood cancers. From 2000 to 2,004 she led a multi-site, multidisciplinary team using chemical proteomics and bioinformatics to discover therapeutic targets and to investigate the mechanism of action of drugs.

Continue reading “Dr. Leticia Toledo-Sherman — Senior Director, Drug Discovery, Tau Consortium, Rainwater Foundation” | >

Interesting.

Everybody knows sleep is important, but there’s still a lot we don’t understand about what it actually does to the brain – and how its benefits could be boosted. To investigate, the US Army has awarded researchers at Rice University and other institutions a grant to develop a portable skullcap that can monitor and adjust the flow of fluid through the brain during sleep.

Most of us are familiar with the brain fog that comes with not getting enough sleep, but the exact processes going on in there remain mysterious. In 2012 scientists made a huge breakthrough in the field by discovering the glymphatic system, which cleans out toxic waste products from the brain during deep sleep by flushing it with cerebrospinal fluid. Disruptions to sleep – and therefore the glymphatic system – have been increasingly associated with neurological disorders such as Alzheimer’s.

Studying the glymphatic system could provide new insights into sleep disorders and how to treat them, but currently it requires big bulky MRI machines. So the US Army is funding researchers at Rice University, Houston Methodist and Baylor College of Medicine to develop a wearable skullcap.

Read more | >